Novo Nordisk v. Orbicular Pharmaceutical: Injection Device Patent Case Consolidated in Delaware
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Novo Nordisk A/S v. Orbicular Pharmaceutical Technologies Pvt., Ltd. |
| Case Number | 1:23-cv-00179 (D. Del.) |
| Court | District of Delaware |
| Duration | Feb 2023 – Apr 2024 419 days |
| Outcome | Case Closed via Consolidation |
| Patents at Issue | |
| Accused Products | Injection button & propylene glycol-containing peptide formulations suitable for injection devices |
Case Overview
The Parties
⚖️ Plaintiff
Danish multinational pharmaceutical company and global leader in diabetes care, known for its extensive patent portfolio covering drug formulations and delivery devices.
🛡️ Defendant
India-based pharmaceutical company focused on generic drug development and manufacturing, challenging branded pharmaceutical patents.
Patents at Issue
This dispute centered on two U.S. patents covering core technologies for modern drug delivery systems, a dual-layer IP strategy common among leading pharmaceutical innovators.
- • U.S. Patent No. 9,265,893 B2 — Covers an **injection button** integral to pen-type drug delivery devices.
- • U.S. Patent No. 8,114,833 B2 — Covers **propylene glycol-containing peptide formulations** optimized for injection devices.
Developing a new drug delivery system or generic formulation?
Check if your product might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
This case was closed via consolidation rather than through a merits determination such as trial verdict, summary judgment, or settlement in this docket. The court’s May 22, 2023 order consolidated Case No. 1:23-cv-00179 with the earlier-filed Lead Case No. 1:22-cv-00856-CFC for all purposes. No independent damages award or injunctive relief determination was rendered within this case number; substantive resolution flows through the lead consolidated action.
Key Legal Issues
The consolidation itself was strategically significant. The earlier-filed companion case likely involves overlapping patents, parties, or accused products. By consolidating, the court avoids inconsistent claim constructions across related proceedings — a critical consideration when multiple patents covering interrelated device and formulation technologies are at issue. For Novo Nordisk, consolidation under a single lead case preserves the coherent narrative of its IP portfolio enforcement. For Orbicular, the consolidation concentrates litigation risk into a single forum but also potentially reduces cumulative litigation costs.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical injection device and formulation development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation for pharma IP.
- View all related patents in this drug delivery space
- See which companies are most active in pharma device IP
- Understand claim construction patterns for injection mechanisms
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own pharmaceutical product or device.
- Input your drug formulation or device design
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Injection Devices & Peptide Formulations
2 Patents Consolidated
In Drug Delivery Space
Clearance Opportunities
Through strategic FTO & design-arounds
✅ Key Takeaways
Consolidation of related pharmaceutical patent cases in Delaware is a powerful case management tool that benefits plaintiffs seeking coherent multi-patent enforcement.
Search related case law →Dual device-and-formulation patent portfolios create layered infringement exposure that complicates generic defense strategies.
Explore precedents →Frequently Asked Questions
Two U.S. patents: U.S. Patent No. 9,265,893 B2 (injection button) and U.S. Patent No. 8,114,833 B2 (propylene glycol-containing peptide formulations for injection devices).
Judge Colm F. Connolly consolidated Case No. 1:23-cv-00179 with the related Case No. 1:22-cv-00856-CFC on May 22, 2023, to streamline overlapping patent infringement proceedings involving the same parties and related technologies under a single lead docket.
It reinforces the importance of multi-patent, multi-layer enforcement strategies covering both device components and drug formulations, and highlights Delaware’s role as the premier venue for coordinated pharmaceutical patent litigation.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER Case Lookup — Case No. 1:23-cv-00179
- USPTO Patent Center — U.S. Patent No. 9,265,893
- USPTO Patent Center — U.S. Patent No. 8,114,833
- District of Delaware Local Patent Rules
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.